NNC 0151-0000-0000 + NNC 0151-0000-0000 + placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammation
Conditions
Inflammation, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Healthy
Trial Timeline
Jun 1, 2008 → Oct 1, 2009
NCT ID
NCT02151409About NNC 0151-0000-0000 + NNC 0151-0000-0000 + placebo
NNC 0151-0000-0000 + NNC 0151-0000-0000 + placebo is a phase 1 stage product being developed by Novo Nordisk for Inflammation. The current trial status is completed. This product is registered under clinical trial identifier NCT02151409. Target conditions include Inflammation, Systemic Lupus Erythematosus, Rheumatoid Arthritis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02151409 | Phase 1 | Completed |
Competing Products
20 competing products in Inflammation